title: [Epidermolysis bullosa acquisita. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie].
authors.affiliation: Service de dermatologie, centre de référence maladies rares, dermatoses bulleuses toxiques et auto-immunes, hôpital Avicenne, UFR Paris 13, 125 rue de Stalingrad, Bobigny cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Prost-Squarcioni
authors.forename: S
authors.initials: S
authors.lastname: Ingen-Housz-Oro
authors.forename: P
authors.initials: P
authors.lastname: Joly
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: C
authors.initials: C
authors.lastname: Bedane
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001706:Biopsy; D003078:Colchicine / Q000008:administration & dosage / Q000627:therapeutic use; D015897:Comorbidity; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D016107:Epidermolysis Bullosa Acquisita / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007159:Immunologic Tests / Q000379:methods; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007167:Immunotherapy; D010348:Patient Care Team; D010353:Patient Education as Topic; D010778:Photochemotherapy; D010808:Physical Examination; D012307:Risk Factors; D000069283:Rituximab
chemical_list: D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003622:Dapsone; D003078:Colchicine